Health Care [ 4/12 ] | Biotechnology [ 11/75 ]
NASDAQ | Common Stock
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs.
Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE).
The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients.
KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 11, 25 | -0.92 Decreased by -1.10% | -0.96 Increased by +4.17% |
| Sep 3, 25 | -1.12 Decreased by -28.74% | -0.90 Decreased by -24.44% |
| Jul 10, 25 | -0.99 Increased by +2.94% | -0.81 Decreased by -22.22% |
| Mar 12, 25 | -0.92 Decreased by -9.52% | -0.87 Decreased by -5.75% |
| Dec 4, 24 | -0.91 Decreased by -13.75% | -0.91 |
| Sep 5, 24 | -0.87 Decreased by -17.57% | -0.91 Increased by +4.40% |
| Jul 11, 24 | -1.02 Decreased by -32.47% | -0.73 Decreased by -39.73% |
| Mar 11, 24 | -0.84 Decreased by -12.00% | -0.77 Decreased by -9.09% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Oct 31, 25 | 59.92 M Increased by +N/A% | -5.37 M Increased by +87.29% | Decreased by -8.96% Decreased by N/A% |
| Jul 31, 25 | 1.43 M Increased by +N/A% | -60.10 M Decreased by -48.59% | Decreased by -4.21 K% Decreased by N/A% |
| Apr 30, 25 | 0.00 Decreased by -100.00% | -52.23 M Decreased by -16.97% | Decreased by N/A% Decreased by N/A% |
| Jan 31, 25 | 0.00 Decreased by N/A% | -48.51 M Decreased by -67.11% | Decreased by N/A% Decreased by N/A% |
| Oct 31, 24 | 0.00 Decreased by N/A% | -42.27 M Decreased by -52.87% | Decreased by N/A% Decreased by N/A% |
| Jul 31, 24 | 0.00 Decreased by N/A% | -40.44 M Decreased by -59.75% | Decreased by N/A% Decreased by N/A% |
| Apr 30, 24 | 1.21 M Increased by +N/A% | -44.65 M Decreased by -69.74% | Decreased by -3.70 K% Decreased by N/A% |
| Jan 31, 24 | 0.00 Decreased by N/A% | -29.03 M Decreased by -36.26% | Decreased by N/A% Decreased by N/A% |